Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
Paolo Tarantino,Paolo Tarantino,Roberto Carmagnani Pestana,Chiara Corti,Chiara Corti,Shanu Modi,Aditya Bardia,Sara M. Tolaney,Javier Cortes,Jean-Charles Soria,Giuseppe Curigliano,Giuseppe Curigliano +11 more
Reads0
Chats0
TLDR
In this article, the authors summarize the current approvals of antibody-drug conjugates (ADCs) by the US Food and Drug Administration focusing on solid tumors and discuss the challenges and opportunities posed by the multihistological expansion of ADCs.Abstract:
As distinct cancer biomarkers have been discovered in recent years, a need to reclassify tumors by more than their histology has been proposed, and therapies are now tailored to treat cancers based on specific molecular aberrations and immunologic markers. In fact, multiple histology-agnostic therapies are currently adopted in clinical practice for treating patients regardless of their tumor site of origin. In parallel with this new model for drug development, in the past few years, several novel antibody-drug conjugates (ADCs) have been approved to treat solid tumors, benefiting from engineering improvements in the conjugation process and the introduction of novel linkers and payloads. With the recognition that numerous surface targets are expressed across various cancer histologies, alongside the remarkable activity of modern ADCs, this drug class has been increasingly evaluated as suitable for a histology-agnostic expansion of indication. For illustration, the anti-HER2 ADC trastuzumab deruxtecan has demonstrated compelling activity in HER2-overexpressing breast, gastric, colorectal, and lung cancer. Examples of additional novel and potentially histology-agnostic ADC targets include trophoblast cell-surface antigen 2 (Trop-2) and nectin-4, among others. In the current review article, the authors summarize the current approvals of ADCs by the US Food and Drug Administration focusing on solid tumors and discuss the challenges and opportunities posed by the multihistological expansion of ADCs.read more
Citations
More filters
Journal ArticleDOI
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
Konstantinos Venetis,E. Crimini,Elham Sajjadi,Chiara Corti,Elena Guerini-Rocco,Giuseppe Viale,Giuseppe Curigliano,Carmen Criscitiello,Nicola Fusco +8 more
TL;DR: An overview of the current state of HER2 targeting in breast cancers beyond the canonical HER2 positivity is provided and the practical implications for pathologists and oncologists are discussed.
Journal ArticleDOI
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.
Eleonora Nicolò,Federica Giugliano,L. Ascione,Paolo Tarantino,Chiara Corti,Sara M. Tolaney,Massimo Cristofanilli,Giuseppe Curigliano +7 more
TL;DR: In this paper , a review of the combination of ADCs and immunotherapy is presented, highlighting the key mechanisms underlying the synergistic effect and providing an overview of the available clinical evidence in solid tumors.
Journal ArticleDOI
Bystander effect of antibody–drug conjugates: fact or fiction?
TL;DR: Preclinical and clinical evidence about bystander effect of antibody–drug conjugates (ADCs) in solid tumors, and the clinical activity of ADCs in tumors with a heterogeneous Ag expression suggests the relevance of this feature, are summarized.
Journal ArticleDOI
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
TL;DR: The claudin18.2 protein has become a unique molecule for targeted therapy in different cancers, especially in GC; for example, agents such as zolbetuximab (claudiximab, IMAB362), a monoclonal antibody (mAb) against CLDN18, have been developed as discussed by the authors .
Journal ArticleDOI
Clinical applications of mass spectrometry‐based proteomics in cancer: Where are we?
TL;DR: The use of DIA-MS in studies that may pave the way for future clinical cancer applications are summarized, the role of alternative MS technologies and multi-omic strategies are highlighted, and steps for integrating proteomic data into the cancer clinic are proposed.
References
More filters
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Dennis J. Slamon,William Godolphin,Lovell A. Jones,John A. Holt,Steven G. Wong,Duane E. Keith,Wendy J. Levin,Susan G. Stuart,Judy Udove,Axel Ullrich,Michael F. Press +10 more
TL;DR: The concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers, including breast and ovarian cancer, is supported.
Journal ArticleDOI
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang,Eric Van Cutsem,A. Feyereislova,Hyun Cheol Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,G. Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang +15 more
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Cancer immunotherapy comes of age
TL;DR: In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.
Journal ArticleDOI
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C. Wolff,M. Elizabeth H. Hammond,David G. Hicks,Mitch Dowsett,Lisa M. McShane,Kimberly H. Allison,D. C. Allred,John M. S. Bartlett,Michael Bilous,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Pamela B. Mangu,Soonmyung Paik,Edith A. Perez,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Daniel F. Hayes +19 more
TL;DR: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive).